Drug-excipient interactions and their affect on absorption

Pharmaceutical Science and Technology Today

Volumn 3, Issue 10, 2000, Pages 336-345

  Jackson, Kimberley ^a   Young, David ^a   Pant, Sonia ^a  

^a ICON Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT;

BIOAVAILABILITY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; DECOMPOSITION; DISSOLUTION; DRUG ABSORPTION; DRUG INTERACTION; EXCIPIENT COMPATIBILITY; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; REVIEW;

EID: 0034306609     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(00)00301-1     Document Type: Review

References (89)

1. The dissolution rate principle in practical tablet formulation
2. Effect of various disintegrants on the availability of directly compressed sulphadimidine tablets
3. Handbook of Pharmaceutical Excipients
4. Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant, II. The choice of super disintegrants and effect of granulation
5. Studies on metronidazole tablet formulation
6. Effect of excipients on tablet properties and dissolution behavior of theophylline-tableted microcapsules under different compression forces
7. Excipients and their functionality in drug product development
8. The effect of the swelling capacity of disintegrants on the in vitro and in vivo availability of diazepam tablets, containing magnesium stearate as a lubricant
9. Interaction of tablet disintegrants and magnesium stearate during mixing, I; effect on tablet disintegration
10. Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants
11. The effect of disintegrants and processing on the bioavailability of frusemide from compressed tablets
12. Comparative bioavailability of praziquantel tablets
13. Drug-disintegrant interactions; binding of oxymorphone derivatives
14. Correlations among dissolution, permeation and bioavailability of phenylbutazone formulations
15. Bioavailability of tolazamide from tablets; comparison of in vitro and in vivo results
16. Dissolution rate and bioavailability of spironolactone tablets; effect of various technological factors
17. Factors influencing comparative bioavailability of spironolactone tablets
18. In vitro and in vivo availability of spironolactone from oral dosage forms
19. Quantification of the effect of excipients on bioavailability by means of response surfaces, I; amoxicillin in fat matrix
20. Quantification of the effect of excipients on bioavailability by means of response surfaces, II; amoxicillin in fat-silica matrix
21. Quantification of the effect of excipients on bioavailability by means of response surfaces, III; in vivo-in vitro correlations
22. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer
23. Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation
24. Application of gluconolactone in direct tablet compression
25. Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate
26. Biological availability and urinary excretion kinetics of oral tolbutamide formulations in man
27. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time
28. The effect of mannitol on the oral bioavailability of cimetidine
29. The effects of pharmaceutical excipients on small intestinal transit
30. The effect of different concentrations of mannitol in solution on small intestinal transit; implications for drug absorption
31. Cyclodextrins; their future in drug formulation and delivery
32. Cyclodextrins, their value in pharmaceutical technology
33. Pharmaceutical applications of cyclodextrins, 2. In vivo drug delivery
34. Pharmaceutical applications of cyclodextrins, 1. Drug solubilization and stabilization
35. Cyclodextrins- enabling excipients; their present and future use in pharmaceuticals
36. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone; preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats
37. Enhancement of bioavailability of griseofulvin by its complexation with β-cyclodextrin
38. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-β-cyclodextrin complexation in healthy volunteers
39. β-cyclodextrin derivatives, SBE4-β-cd and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs
40. Comparative pharmacokinetic and bioavailability studies of atovaquone in dogs, I. Cyclodextrin complexation
41. Oral bioavailability of naproxen-β-cyclodextrin inclusion compound
42. Bioavailability study of tolbutamide β-cyclodextrin inclusion compounds, solid dispersions and bulk powder
43. Applied Biopharmaceutics and Pharmacokinetics
44. Effect of inert tablet ingredients on drug absorption, I. Effect of polyethylene glycol 4000 on the intestinal absorption of four barbiturates
45. Dissolution-dialysis method of assessing in vitro drug availability of prednisolone tablets
46. Effects of interaction with surfactants, adsorbents, and other substances on the permeation of chlorpromazine through a dimethyl polysiloxane membrane
47. Improved dissolution rate of indomethacin by adsorbents
48. Drug-excipient interactions
49. Alterations in absorption of dicumarol by various excipient materials
50. Excipient interaction with cetylpyridinium chloride activity in tablet based lozenges
51. Drug permeation through membranes, IV; effect of excipients and various additives on permeation of chlordiazepoxide through polydimethylsiloxane membranes
52. An in vitro study of the interaction between diazepam and some antacids or excipients
53. Estimation of the extent of drug-excipient interactions involving croscarmellose sodium
54. Bioavailability of phenylpropanolamine HCL from tablet dosage forms containing croscarmellose sodium
55. Increasing dissolution rates of poorly soluble drugs by adsorption to montmorillonite
56. Preparation, characterization and dissolution of ciprofloxacin/PEG 6000 binary systems
57. Formulation and In vitro-in vivo characterization of solid dispersions of piroxicam
58. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits
59. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions
60. Dissolution and absorption of nifedipine in polyethylene glycol solid dispersion containing phosphatidylcholine
61. Dissolution behaviour of drugs from binary and ternary systems
62. Product development studies on the tablet formulation of ibuprofen to improve bioavailability
63. Comparative dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems and tablets
64. Dissolution, bioavailability and ulcerogenic studies on solid dispersions of indomethacin in water soluble cellulose polymers
65. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans
66. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions
67. Improved dissolution of a poorly water-soluble drug from solid dispersions in polyethylene glycol:polysorbate 80 mixtures
68. Factors involved in an outbreak of phenytoin intoxification
69. Outbreak of anticonvulsant intoxication in an Australian city
70. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food
71. Bioavailability of phenytoin; clinical pharmacokinetic and therapeutic implications
72. Some factors influencing the in vitro release of phenytoin from formulations
73. Effect of silica gel on stability and biological availability of ascorbic acid
74. Use of chitosan in compressed tablets of diclofenac sodium; inhibition of drug release in an acidic environment
75. The dissolution and complexing properties of ibuprofen and ketoprofen when mixed with N-methylglucamine
76. Guidance for Industry: SUPAC-IR: Immediate Release Solid Oral Dosage Forms. Scale-up and Post-approval Changes: Chemistry, Manufacturing and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation
77. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms. Scale-up and Post-approval Changes: Chemistry, Manufacturing and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation
78. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules
79. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets
80. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations
81. Study of the dissolution characteristics of oxazepam via complexation with beta cyclodextrin